Das pharmakologische Profil von Sildenafil zeigt neben der PDE5-Inhibition auch eine geringe Aktivität an der PDE6 in der Retina. Dies erklärt visuelle Nebenwirkungen wie Farbsehstörungen, die gelegentlich auftreten. Die orale Bioverfügbarkeit beträgt etwa 40 %, mit einer hohen Bindung an Plasmaproteine. Das Verteilungsvolumen ist groß, sodass die Substanz rasch in verschiedene Gewebe gelangt. Die Metabolisierung erfolgt hepatisch und produziert einen aktiven Metaboliten, der die pharmakologische Wirkung ergänzt. Nebenwirkungen sind dosisabhängig und umfassen Kopfschmerzen, Hautrötung und Dyspepsie. Bei Vergleichen innerhalb der Wirkstoffklasse wird viagra original regelmäßig als Beispiel für eine Substanz mit schneller, aber kurzzeitiger Wirkung aufgeführt.
Microsoft word - effect of modafinil on the pharmacokinetics of ethinyl estr
Effectof modafinil on the pharmacokinetics of ethinyl estradiol andtriazolamin healthy volunteers. Clin Pharmacol Ther 2002 Jan;71(1):46-56 (ISSN: 0009-9236) Robertson P; Hellriegel ET; Arora S; Nelson M Department of Drug Disposition, Cephalon, Inc., West Chester, PA 19380, USA. [email protected]. BACKGROUND: Modafinil has been reported to produce a concentration-related induction of CYP3A4/5 activity in vitro in primary cultures ofhuman hepatocytes. OBJECTIVE: Our objective was to determine whether the pharmacokinetics of steady-state ethinyl estradiol (INN, ethinylestradiol) andsingle-dosetriazolam were altered after 4 weeks of modafinil treatment in volunteers. METHODS: This was a placebo-controlled, single-blind, single-period study in 41 female subjects who were receiving long-term treatment with an oral contraceptive that contained ethinyl estradiol (0.035 mg) and norgestimate (0.180-0.250 mg). Pharmacokinetic profiles for ethinyl estradiol and for a single oral doseoftriazolam (0.125 mg) were obtained the day before initiation of treatment with modafinil (200 mg for 7 days, followed by 400 mg for 21 days) or placebo (28 days). A second doseoftriazolam was administered with the final doseof modafinil, and pharmacokinetic profiling was repeated. RESULTS: The modafinil treatment group had a marked decrease in maximum observed plasma concentrations and areas under the plasma concentration-time curve for triazolam relative to placebo, with a much smaller decrease in these parameters for ethinyl estradiol. The half-lifeoftriazolam was also decreased, but the half-lifeof ethinyl estradiol did not appear to be affected by treatment with modafinil. CONCLUSION: Modafinil induced CYP3A4/5 activity inhumansin vivo, suggesting that there is potential for metabolic drug-drug interactions between modafinil and substrates of CYP3A4/5. However, the induction appeared to be more gastrointestinal than hepatic in nature. Therefore significant metabolic drug-drug interactions are most likely to occur with compounds (such as triazolam) that undergo significant gastrointestinal CYP3A4/5-mediated first-pass metabolism. CAS Registry / EC Major Subject Heading(s) Minor Subject Heading(s)
Chromatography, High
28911-01-5 (Triazolam)
Triazolam
Half-Life
Human
protein, human)
Mixed Function Oxygenases EC 1.14.14.1 (nifedipine [metabolism]
Sedatives, Nonbarbiturate [adverse effects]
Single-Blind Method
Spectrophotometry, Ultraviolet Spectrum Analysis, Mass
Triazolam [adverse effects]
Scandalous Lies About Cholesterol Cholesterol is absolutely not unhealthy, produces most of the required cholesterol. but essential. Would that be the case if cholesterol was un-healthy ? Decreased blood-cholesterol level causes de-pressions and sleeplessness, as a warning Of course not. You can say nature is cruel or whatever, but no one can say nature is illogi-cal. The only